Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: Subgroup analysis from the PREDICTIVE™ study

International Journal of Clinical Practice

Volumn 62, Issue 4, 2008, Pages 659-665

  Dornhorst, A ^a   Luddeke H J ^b   Sreenan, S ^c   Kozlovski, P ^d   Hansen, J B ^d   Looij, B J ^e   Meneghini, L ^f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Praxis Lüddeke Trauner   (Germany)

^c Royal College of Surgeons in Ireland   (Ireland)

^d NOVO NORDISK A S   (Denmark)

^e Sittard Geleen Heerlen   (Netherlands)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR;

ADULT; AGED; ARTICLE; BODY MASS; CARBOHYDRATE INTAKE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MULTICENTER STUDY; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN; PREDICTOR VARIABLE; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 40449141977     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01715.x     Document Type: Article

References (23)

1. Wright A, Burden AC, Paisey EB et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002 25 : 330 6.
2. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
3. Home PD, Boulton AJM, Jimenez J et al. Issues relating to the early or earlier use of insulin in type 2 diabetes. Practical Diabetes Int 2003 20 : 63 71.
4. Ohkubo Y, Kishikawa H, Miyata T et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 28 : 103 17.
5. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 348 : 383 93.
6. Berger M, Jorgens V, Muhlhauser I. Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes. Diabetes Care 1999 22 (Suppl. 3 C71 5.
7. Glaser B, Cerasi E. Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. Diabetes Obes Metab 1999 1 : 67 74.
8. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 : 1963 72.
9. 1c levels exceed recommended targets prior to initiation or intensification of insulin therapy in clinical practice: baseline data from the PREDICTIVE™ European cohort. EASD 2006, Abstract 0897.
10. Farmer A, Kinmonth AL, Suton S. Measuring beliefs about taking hypoglycaemic medication among people with type 2 diabetes. Diabet Med 2006 23 : 265 70.
11. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999 46 : 239 46.
12. Hermansen K, Davies M, Derezinski T et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006 29 : 1269 74.
13. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003 26 : 3080 6.
14. Klein O, Lynge J, Endahl L et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007 9 : 290 9.
15. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007 9 : 648 59.
16. Rosenstock J, Davies M, Home PD et al. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes 2006 55 : A132.
17. Lüddeke H-J, Philotheou A, Horn-Rosenberg K et al. PREDICTIVE™: a global, prospective, observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes - 3-month follow-up data. Diabetic Medicine 2006 23 (Suppl 4) 139 : Abstract 380.
18. Lüddeke H-J, Sreenan S, Aczel S et al. PREDICTIVE™: a global, prospective, observational study to evaluate insulin detemir treatment in type 1 and 2 diabetes - baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007 (In press).
19. Yki-Jarvinen H, Kauppila M, Kujansuu E et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992 327 : 1426 33.
20. Yki-Jarvinen H, Ryysy L, Nikkila K et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999 130 : 389 96.
21. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006 49 : 442 51.
22. Haak T, Tiengo A, Draeger E et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005 7 : 56 64.
23. Rašlová K, Bogoev M, Raz I et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004 66 : 193 201.